NeoGenomics (NEO), a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.
The company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share (EPS) of $0.04, slightly above the consensus estimate of $0.03.
However, the more significant factor contributing to the stock's plummet was the company's full-year 2025 guidance, which failed to meet investor expectations. While NeoGenomics reaffirmed its revenue guidance range of $735 million to $745 million for 2025, representing growth of 11% to 13% year-over-year, the midpoint of $740 million was only 0.7% above analysts' estimates. Furthermore, the company's adjusted EPS guidance range of $0.15 to $0.19 for 2025 disappointed investors, with the midpoint of $0.17 falling short of the consensus estimate of $0.20.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。